Technical Analysis for ZYME - Zymeworks Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| NR7 | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Down 4 Days in a Row | Weakness | 0.00% | |
| Down 5 Days in a Row | Weakness | 0.00% | |
| Fell Below 20 DMA | Bearish | -1.49% | |
| New Downtrend | Bearish | -1.49% | |
| Wide Bands | Range Expansion | -1.49% | |
| Down 3 Days in a Row | Weakness | -1.49% |
| Alert | Time |
|---|---|
| Possible NR7 | about 18 hours ago |
| Fell Below Previous Day's Low | about 22 hours ago |
| Down 2 % | about 22 hours ago |
| Down 1% | about 22 hours ago |
| 20 DMA Resistance | 2 days ago |
Get a Trading Assistant
- Earnings date: 10/31/2024
Zymeworks Inc. Description
Zymeworks Inc is a Canada-based clinical-stage biopharmaceutical company. The Company focuses on the discovery, development and commercialization of multifunctional biotherapeutics. The Company's ZymeCAD platform is for protein modeling and structure-guided protein engineering. The Company's platforms include Azymetric Platform, AlbuCORE Platform, EFECT Platform and Zymelink Conjugation Platform + Cytotoxins. The Company's lead product candidate, ZW25, is a bispecific antibody, which is being evaluated in an adaptive Phase I clinical trial. Its ZW33 is a bi-specific antibody that delivers a cytotoxic payload to cancers cells by binding to different epitopes (bi-paratopic targeting) of the overexpressed HER2 protein. It focuses on developing a pipeline of preclinical product candidates and discovery-stage programs in immuno-oncology and other therapeutic areas. It analyzes protein characteristics to develop the scope of protein engineering to tackle biological systems.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Immunology Immune System Cancer Immunotherapy Monoclonal Antibodies Antibody Toxins Glycoproteins Her2 Protein Engineering Biological Systems Bispecific Monoclonal Antibody
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 17.67 |
| 52 Week Low | 7.97 |
| Average Volume | 456,722 |
| 200-Day Moving Average | 10.94 |
| 50-Day Moving Average | 13.67 |
| 20-Day Moving Average | 14.99 |
| 10-Day Moving Average | 16.12 |
| Average True Range | 0.68 |
| RSI (14) | 48.19 |
| ADX | 27.79 |
| +DI | 28.93 |
| -DI | 29.90 |
| Chandelier Exit (Long, 3 ATRs) | 15.63 |
| Chandelier Exit (Short, 3 ATRs) | 14.43 |
| Upper Bollinger Bands | 17.95 |
| Lower Bollinger Band | 12.04 |
| Percent B (%b) | 0.42 |
| BandWidth | 39.45 |
| MACD Line | 0.58 |
| MACD Signal Line | 0.79 |
| MACD Histogram | -0.212 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 15.05 | ||||
| Resistance 3 (R3) | 15.06 | 14.91 | 14.96 | ||
| Resistance 2 (R2) | 14.91 | 14.78 | 14.90 | 14.93 | |
| Resistance 1 (R1) | 14.73 | 14.71 | 14.66 | 14.72 | 14.91 |
| Pivot Point | 14.58 | 14.58 | 14.54 | 14.57 | 14.58 |
| Support 1 (S1) | 14.40 | 14.45 | 14.33 | 14.39 | 14.19 |
| Support 2 (S2) | 14.25 | 14.38 | 14.24 | 14.17 | |
| Support 3 (S3) | 14.07 | 14.25 | 14.14 | ||
| Support 4 (S4) | 14.06 |
